Stock Ratings / Health Care / PRPO / financials

EYPT (38) RPID (47) HBIO (44) BNGO (36) ⌘ Pro Terminal →

Precipio Inc. (PRPO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Precipio Inc. (PRPO)?

In FY 2025 (10-K), PRPO converted $24.2M of revenue into a 44.2% gross margin, 0% operating margin, and $359000 in free cash flow (1.5% FCF margin).

$19.35 +3.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Precipio Inc. (PRPO) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $34.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRPO)Realized 20D OHLCV Swing Band: ±10.2%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PRPO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$359.0K (1.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $15.4M

FY24

Rev $18.6M

FY25

Rev $24.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$24.2M	44.2%	-5%	-$363.0K	$359.0K	-7.9%
FY 2024	$18.6M	40.7%	-22.7%	-$4.3M	$216.0K	-30.9%
FY 2023	$15.4M	44.2%	-49.4%	-$5.9M	-$3.6M	-7.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRPO)

✓Walkthrough of PRPO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRPO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.38%▼ DESCENDING CHANNEL

2026-10-30O $19.83H $19.83L $17.99C $19.35VOL 25.9K

RES: $31.94SUP: $15.34SMA50: $24.58SMA200: $24.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRPO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRPO Butterfly Map → + Track PRPO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +30.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRPO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRPO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRPO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRPO)

Health Care Rank #723 of 1016 ⚔️ EYPT vs PRPO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRPO vs. EYPT, RPID, HBIO, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Precipio Inc. (PRPO) ranks #723 by composite RQD confidence (38/100, grade D-) and #790 by equity capitalization ($34.6M). Within this direct 5-issuer industry benchmark cohort, PRPO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PRPO at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRPO ACTIVE Precipio Inc.	D-	38/100	—	44.2%	-7.9%	+3.59%	$34.6M	Benchmark Subject
EYPT EyePoint Inc.	D-	38/100	—	—	-35.0%	+0.69%	$32.8M	/eypt-vs-prpo →
RPID Rapid Micro Biosystems Inc. (Class A)	D	47/100	—	—	-35.0%	-1.37%	$39.6M	/rpid-vs-prpo →
HBIO Harvard Bioscience Inc.	D	44/100	—	57.7%	-35.0%	+4.51%	$40.1M	/hbio-vs-prpo →
BNGO Bionano Genomics Inc.	D-	36/100	—	46.3%	-35.0%	-0.41%	$16.8M	/bngo-vs-prpo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001043961

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precipio Inc. (PRPO) reported GAAP revenue of $24.2M (+30.5% vs. FY2024 revenue of $18.6M , and +57.3% cumulative change since FY2023) , GAAP net income of -$363.0K, operating cash flow of $685.0K, and free cash flow of $359.0K (+66.2% YoY). On the balance sheet, PRPO closed FY2025 with $21.3M in total assets against $47.0K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$24.2M	-$363.0K	$685.0K	$359.0K	$21.3M	$47.0K
FY2024 (FY)	2024-12-31	$18.6M	-$4.3M	$439.0K	$216.0K	$17.0M	$77.0K
FY2023 (FY)	2023-12-31	$15.4M	-$5.9M	-$3.6M	-$3.6M	—	—

3. PRPO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Precipio Inc. (NASDAQ: PRPO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $19.35 (+3.59% 1D, market cap $34.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, PRPO ranks #723 in composite RQD confidence.

How does PRPO compare to EYPT and RPID in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $32.8M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $39.6M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRPO?

Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRPO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRPO last traded at $19.35 (+3.59% on volume of 10,967 shares), positioning the stock -21.28% below its 50-day simple moving average ($24.58) and -22.57% below its 200-day simple moving average ($24.99). Across its 52-week range of $17.99 to $33.63, PRPO sits at the 8.7% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±10.2% ($17.38 to $21.32).